In trading on Wednesday, shares of CrossAmerica Partners LP (CAPL - Get Report) entered into oversold territory, changing hands as low as $23.02 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In the case of CrossAmerica Partners LP, the RSI reading has hit 26.9 — by comparison, the universe of energy stocks covered by Energy Stock Channel currently has an average RSI of 48.6, the RSI of WTI Crude Oil is at 56.6, the RSI of Henry Hub Natural Gas is presently 45.3, and the 3-2-1 Crack Spread RSI is 33.9. A bullish investor could look at CAPL's 26.9 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), CAPL's low point in its 52 week range is $23.02 per share, with $29.80 as the 52 week high point — that compares with a last trade of $23.18. CrossAmerica Partners LP shares are currently trading off about 2.4% on the day. According to the ETF Finder at ETF Channel, CAPL makes up 6.66% of the Guggenheim International Multi-Asset Income ETF ( HGI) which is trading lower by about 0.7% on the day Wednesday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Financial Market Behavior, General Mills Earnings: Market Recon
Markets must choose now between the easy, the tense and the uncertain. What could possibly go wrong?
Del Frisco's to Be Acquired for $650 Million by Private-Equity Firm L Catterton
Del Frisco's is being acquired by private-equity firm L Catterton for $8 a share.
Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
Bristol-Myers Squibb shares slumped lower in pre-market trading Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.
Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears
U.S. stocks look set to test all time highs again Monday, following a third consecutive weekly gain for all three benchmarks on Wall Street, as investors continue to bet that central bank support will boost global equities and this weekend's G20 Summit in Osaka will trigger a breakthrough in U.S.-China trade talks.